180 Life Sciences Corp. - notizie pubblicate 234 - letture 8.932
180 LIFE SCIENCES CORP.
Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement - Form 8-K
180 life sciences regains full compliance with nasdaq minimum bid price requirement palo alto, calif., january 5, 2023 -- 180 life sciences corp. (nasdaq: atnf) ("180 life sci ...
180 LIFE SCIENCES CORP.
180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement
180 life sciences regains full compliance with nasdaq minimum bid price requirement january 05, 2023 8:30am est download as pdf palo alto, calif., jan. 05, 2023 (globe newswire) -- ...
180 LIFE SCIENCES CORP.
Life Sciences Announces Publication of a Review on the Biological Basis of Dupuytren’s Disease - Form 8-K
180 life sciences announces publication of a review on the biological basis of dupuytren's disease palo alto, calif., january 4, 2023 -- 180 life sciences corp. (nasdaq: atnf) (&qu ...
180 LIFE SCIENCES CORP.
180 Life Sciences Announces Publication of a Review on the Biological Basis of Dupuytren’s Disease
180 life sciences announces publication of a review on the biological basis of dupuytren's disease january 04, 2023 8:30am est download as pdf palo alto, calif., jan. 04, 2023 (glo ...
180 LIFE SCIENCES CORP.
Material Agreement - Form 8-K
United states securities and exchange commission washington, d.c. 20549 form 8-k current report pursuant to section 13 or 15(d) of the securities exchange act of 1934 date of repor ...
180 LIFE SCIENCES CORP.
Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Shareholders - Form 8-K
180 life sciences corp. ceo james woody, md, phd issues letter to shareholders dear fellow shareholder, as we come to the end of 2022, i am pleased to provide an update for our sha ...
180 LIFE SCIENCES CORP.
180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Shareholders
180 life sciences corp. ceo james woody, md, phd issues letter to shareholders december 29, 2022 8:30am est download as pdf palo alto, calif., dec. 29, 2022 (globe newswire) -- dea ...
180 LIFE SCIENCES CORP.
180 Life Sciences Corp. Announces Closing of $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
180 life sciences corp. announces closing of $6 million registered direct offering priced at-the-market under nasdaq rules december 23, 2022 8:00am est download as pdf palo alto, c ...
180 LIFE SCIENCES CORP.
Supplemental Prospectus - Form 424B5
Filed pursuant to rule 424(b)(5) registration no. 333-265416 prospectus supplement (to prospectus dated june 24, 2022) 215,000 shares of common stock pre-funded warrants to purchas ...
180 LIFE SCIENCES CORP.
Life Sciences Corp. Announces $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Form 8-K
180 life sciences corp. announces $6 million registered direct offering priced at-the-market under nasdaq rules palo alto, calif., december 20, 2022 (globe newswire) -- 180 life sc ...
180 LIFE SCIENCES CORP.
180 Life Sciences Corp. Announces $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
180 life sciences corp. announces $6 million registered direct offering priced at-the-market under nasdaq rules december 20, 2022 2:11pm est download as pdf palo alto, calif., dec. ...
180 LIFE SCIENCES CORP.
180 Life Sciences Corp. Announces 1-for 20 Reverse Stock Split as Part of Nasdaq Compliance Plan
180 life sciences corp. announces 1-for 20 reverse stock split as part of nasdaq compliance plan december 16, 2022 9:00am est download as pdf palo alto, calif., dec. 16, 2022 (glob ...
180 LIFE SCIENCES CORP.
Life Sciences provides update on progress to seek Medicines and Healthcare products Regulatory Agency marketing authorization for anti-TNF treatment of early stage Dupuytren’s contracture - Form 8-K
180 life sciences provides update on progress to seek medicines and healthcare products regulatory agency marketing authorization for anti-tnf treatment of early stage dupuytren's ...
180 LIFE SCIENCES CORP.
180 Life Sciences Provides Update on Progress To Seek Medicines and Healthcare Products Regulatory Agency Marketing Authorization for Anti-TNF Treatment of Early Stage Dupuytren’s Contracture
180 life sciences provides update on progress to seek medicines and healthcare products regulatory agency marketing authorization for anti-tnf treatment of early stage dupuytren's ...
180 LIFE SCIENCES CORP.
180 Life Sciences to Participate in A.G.P.’s Virtual Biotech Conference to be Held November 30 – December 1, 2022
180 life sciences to participate in a.g.p.'s virtual biotech conference to be held november 30 - december 1, 2022 november 21, 2022 8:30am est download as pdf palo alto, calif., no ...
Per i consulenti finanziari
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti